These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 29090344)

  • 41. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
    Stein EM
    Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Babakhanlou R; DiNardo C; Borthakur G
    Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
    Liu X; Gong Y
    Biomark Res; 2019; 7():22. PubMed ID: 31660152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
    Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
    Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
    Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
    Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
    [No Abstract]   [Full Text] [Related]  

  • 46. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
    Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
    Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
    Waitkus MS; Diplas BH; Yan H
    Cancer Cell; 2018 Aug; 34(2):186-195. PubMed ID: 29805076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2).
    Nayarisseri A; Bandaru S; Khan A; Sharma K; Bhrdwaj A; Kaur M; Ghosh D; Chopra I; Panicker A; Kumar A; Saravanan P; Belapurkar P; Mendonça Junior FJB; Singh SK
    Adv Protein Chem Struct Biol; 2024; 141():223-253. PubMed ID: 38960475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
    Falini B; Sportoletti P; Brunetti L; Martelli MP
    Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.
    Kowalczyk A; Zarychta J; Lejman M; Latoch E; Zawitkowska J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
    Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
    Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.
    Lachowiez C; DiNardo CD; Stein E
    Cancer J; 2022 Jan-Feb 01; 28(1):21-28. PubMed ID: 35072370
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
    Clark O; Yen K; Mellinghoff IK
    Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
    Dang L; Su SM
    Annu Rev Biochem; 2017 Jun; 86():305-331. PubMed ID: 28375741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
    Issa GC; DiNardo CD
    Blood Cancer J; 2021 Jun; 11(6):107. PubMed ID: 34083508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.